About
Neurophyxia is a clinical-stage drug development company focusing on neuroprotective drugs to reduce brain damage caused by oxygen shortage. Its lead product, 2-IB, is in Phase IIb/III trials for stroke, with additional indications including birth asphyxia and cardiac arrest.
Explore Neurophyxia's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.